Tech startups are popping up across industries from real estate to oil and gas, and these three founders are among the leaders in technology. Courtesy images

Often, technology and innovation are mistaken for each other. While not mutually exclusive, both tech and innovation work well together in Houston across all industries — from oil and gas to real estate and social media. These three founders engaged technology for their individual startups.

Srini Katta, founder and CEO of Social Chains

Courtesy of Social Chains

As a social media user, your data is already out there and being used for marketing purposes. But, rather than the Facebooks or Googles of the world making a profit, Srini Katta wanted to create a platform where users made a profit off their own data.

"On our platform, the user is a stakeholder. Our platform distributes 50 percent of the profits to the users," he says.

Social Chains already has 5,000 users and, Katta says, that's with little to no marketing efforts, which Katta is about to launch.

Martin Kay, founder and CEO of Entera Technology

Courtesy of Entera

Martin Kay, who splits his time between Houston and the Bay Area for his startup Entera Technologies, knew there had to be a better way for people searching for a home to buy. He drew a comparison between homebuyers and Netflix viewers to create Entera's software.

"We're a little bit like Netflix," he says. "They go out and get content from everyone, and they begin to watch your behavior. So, Netflix has 2,000 profiles and you probably fit five or six of those. We have almost 100 profiles and what we do is say, we're going to understand what you want, watch your behavior and instead of giving you 40,000 properties on a big map, we actually match you based on your preferences, to the five or six houses that are best for you."

Houston-based Entera has grown as the platform loads more and more data for its users to engage with.

Luther Birdzell, CEO and founder of OAG Analytics

Courtesy of OAG Analytics

Luther Birdzell always knew he wanted to run his own company, but the software and analytics professional worked in various industries before realizing that oil and gas had a huge opportunity for savings using analytics. He founded OAG Analytics in 2013 to help provide a solution for these companies.

"When I founded OAG Analytics, our mission then — and still is today — was to build a platform for the upstream oil and gas industry that enables them to manage their data, introduces world-class machine learning in minutes without having to write a single line of code, and allow them to run simulations on the resulting analysis," Birdzell says.

The company has grown to 25 employees and tripled its revenue last year. The team is forecasting another year of high grow for 2019.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”